Empagliflozin/Metformin Hcl
Brand name: Synjardy Xr
Rank #135 of 500 drugs by total cost
$119.7M
Total Cost
121,366
Total Claims
$119.7M
Total Cost
4,067
Prescribers
$986
Cost per Claim
14,319
Beneficiaries
205,365
30-Day Fills
$29K
Avg Cost/Provider
30
Avg Claims/Provider
About Empagliflozin/Metformin Hcl
Empagliflozin/Metformin Hcl (sold as Synjardy Xr) was prescribed 121,366 times by 4,067 Medicare Part D providers in 2023, costing the program $119.7M. At $986 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 132 | Dronedarone Hcl (Multaq) | $123.4M | 98,156 |
| 133 | Brimonidine Tartrate/Timolol (Brimonidine Tartrate-Timolol) | $122.0M | 361,001 |
| 134 | Olaparib (Lynparza) | $121.1M | 8,744 |
| 135 | Empagliflozin/Metformin Hcl (Synjardy Xr) | $119.7M | 121,366 |
| 136 | Edaravone (Radicava Ors) | $119.6M | 8,588 |
| 137 | Insulin Regular, Human (Afrezza) | $119.4M | 143,017 |
| 138 | Ezetimibe (Ezetimibe) | $118.1M | 2,859,001 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology